Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Rifampicin · 1 trial · 1 indication
Pharmacokinetic parameter Cmax of abiraterone was measured when abiraterone acetate was administered in Period 1 and Period 2.
Pharmacokinetic parameter AUC of abiraterone was measured when abiraterone acetate was administered in Period 1 and Period 2.
Pharmacokinetic parameter tmax of abiraterone was measured when abiraterone acetate was administered in Period 1 and Period 2.
Pharmacokinetic parameter t1/2 of abiraterone was measured when abiraterone acetate was administered in Period 1 and Period 2.
| Arm | Type | Description |
|---|---|---|
| Abiraterone acetate + Rifampicin | EXPERIMENTAL | Abiraterone acetate 1,000 mg (4 x 250 mg) on Day 1 of Period 1. Rifampicin 600 mg (2 x 300 mg) on Days 8 to 13, and Abiraterone acetate 1,000 mg (4 x 250 mg) on Day 14 of Period 2. |
| Name | Type | Description |
|---|---|---|
| Abiraterone acetate | DRUG | Type=exact number, unit=mg, number=1,000, form=tablet, route=oral. Abiraterone acetate administered on Day 1 of Period 1, and Day 14 of Period 2. |
| Rifampicin | DRUG | Type=exact number, unit=mg, number=600, form=capsule, route=oral. Rifampicin administered on Days 8 to 13 of Period 2. |
Inclusion Criteria: * Must have blood pressure between 90 and 140 mmHg systolic, inclusive, and no higher than 90 mmHg diastolic * Must have a 12-lead electrocardiogram consistent with normal cardiac conduction and function * Must sign an informed consent document indicating they understand the pur...
Rifampicin is an investigational small molecule being studied for its effect on the pharmacokinetics of abiraterone in healthy male participants. It is not approved for any indication and is currently in Phase 1 clinical development.
Rifampicin is being developed by Johnson & Johnson (NYSE: JNJ). The company is conducting clinical research on this drug in healthy volunteers.
Rifampicin is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed.
Rifampicin has one completed clinical trial, NCT01655147, titled "A Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Abiraterone in Healthy Male Participants." This Phase 1 study enrolled 19 healthy male participants in Belgium.
Rifampicin is not FDA approved. It is an investigational drug currently in Phase 1 clinical development, and its safety and efficacy have not been established for any medical use.